Arvinas, Inc.
Description
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
About
CEO
Dr. John G. Houston Ph.D.
Employees
445
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
5 Science Park, New Haven, CT 06511, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 28, 2025 | — | — | — | — |
| Jul 28, 2025 | — | — | — | — |
| May 1, 2025 | — | — | — | — |
| Feb 25, 2025 | -1.09 | — | — | — |
| Oct 30, 2024 | -0.96 | -0.68 | 0.28 | -29.17% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 7 | — | 18 |
| Average estimate | — | -1.24 | — | -4.68 |
| Low estimate | — | -1.64 | — | -7.82 |
| High estimate | — | -0.96 | — | -2.28 |
| Last year EPS | — | -0.97 | — | -3.10 |
[stock_revenue_estimate]
Growth estimates
Current qtr
62.110%
Next qtr. (Mar 2025)
-27.690%
Current year
53.120%
Next year (Dec 2025)
-50.720%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 78.50M | 131.40M | 53.60M | 25.90M | 43.00M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 379.70M | 315.00M | 180.40M | 108.40M | 67.20M |
| Selling general and admin | 100.30M | 79.60M | 61.60M | 38.30M | 27.30M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -401.50M | -263.20M | -188.40M | -120.80M | -51.50M |
| Non operating interest income | |||||
| Income | 38.80M | 12.00M | 1.80M | 3.50M | 4.60M |
| Expense | — | — | 100,000 | 65,000 | 100,000 |
| Other income expense | -1.20M | 200,000 | 2.50M | 2.10M | -23.30M |
| Pretax income | -363.90M | -251.00M | -184.10M | -115.20M | -70.30M |
| Tax provision | 900,000 | 20.90M | — | — | — |
| Net income | -367.30M | -282.50M | -191.00M | -119.30M | -70.30M |
| Basic EPS | -6.62 | -5.31 | -3.82 | -3.02 | -2.13 |
| Diluted EPS | -6.62 | -5.31 | -3.82 | -3.02 | -2.13 |
| Basic average shares | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M |
| Diluted average shares | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M |
| EBITDA | -394.80M | -255.00M | -182.40M | -116.70M | -67.90M |
| Net income from continuing op. | -367.30M | -282.50M | -191.00M | -119.30M | -70.30M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.30B | 1.27B | 1.58B | 717.40M | 301.64M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 311.70M | 81.30M | 108.30M | 588.40M | 9.21M |
| Other short term investments | 949.30M | 1.12B | 1.39B | 100.20M | 271.66M |
| Accounts receivable | — | 1.00M | 15.00M | 1.00M | — |
| Other receivables | 7.20M | 7.00M | 10.70M | 7.40M | 6.28M |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 19.70M | 6.10M | 3.73M |
| Restricted cash | 5.50M | 5.50M | 4.50M | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 6.50M | 21.40M | 19.70M | 6.10M | 3.73M |
| Non current assets | |||||
| Properties | 21.00M | 21.50M | 17.50M | 13.10M | 10.32M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 2.60M | 2.00M | 1.40M | 1.20M | 865,888 |
| Construction in progress | — | — | — | — | — |
| Leases | 11.50M | 10.90M | 8.40M | 6.10M | 2.81M |
| Accumulated depreciation | -21.10M | -16.60M | -10.70M | -6.10M | -3.26M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 10.40M | 21.60M | 25.00M | 28,777 | 26,757 |
| Total liabilities | 644.60M | 703.90M | 799.90M | 75.20M | 74.96M |
| Current liabilities | |||||
| Accounts payable | 17.80M | 5.70M | 31.30M | 7.10M | 4.56M |
| Accrued expenses | 48.00M | 40.00M | 10.70M | 9.90M | 1.79M |
| Short term debt | 1.90M | 1.80M | 1.10M | 1.00M | 673,896 |
| Deferred revenue | 163.00M | 218.60M | 206.20M | 22.20M | 19.98M |
| Tax payable | 700,000 | 10.30M | — | — | — |
| Pensions | 25.70M | 18.70M | 12.40M | 9.00M | 5.81M |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 1.30M | 3.70M | 3.90M | 3.10M | 3.71M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 100,000 | 100,000 | — | — | 38,461 |
| Retained earnings | -1.33B | -965.40M | -682.90M | -491.90M | -372.56M |
| Other shareholders equity | -3.10M | -19.20M | -4.60M | 600,000 | 107,576 |
| Total shareholders equity | 660.00M | 564.90M | 781.70M | 642.20M | 226.69M |
| Additional paid in capital | 2.00B | 1.55B | 1.47B | 1.13B | 599.10M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -367.30M | -282.50M | -191.00M | -119.30M | -70.30M | -41.48M | -24.05M | -14.35M |
| Depreciation | 6.70M | 8.20M | 6.00M | 4.10M | 2.30M | 706,000 | 347,395 | 436,329 |
| Deferred Taxes | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 71.60M | 75.50M | 57.10M | 30.20M | 20.10M | 11.63M | 245,048 | 525,586 |
| Other Non-Cash Items | -15.30M | 7.50M | 9.80M | 1.70M | 200,000 | 266,032 | 362,072 | 556,416 |
| Accounts Receivable | 800,000 | 17.70M | -30.20M | -2.20M | -1.20M | 21.01M | -24.63M | -578,926 |
| Accounts Payable | 17.30M | 20.20M | 27.90M | 12.80M | 1.50M | 2.00M | -969,479 | 1.20M |
| Other Assets & Liabilities | -76.60M | -118.70M | 694.20M | -14.20M | 4.30M | -8.55M | 103.84M | -13.18M |
| Operating Cash Flow | -362.80M | -272.10M | 573.80M | -86.90M | -43.10M | -14.42M | 55.15M | -25.39M |
| Investing Activities | ||||||||
| Capital Expenditures | -2.90M | -6.80M | -4.70M | -6.40M | -6.30M | -2.83M | -1.01M | -256,667 |
| Net Intangibles | — | — | — | — | — | — | — | -50,000 |
| Net Acquisitions | — | — | — | — | — | — | — | — |
| Purchase of Investments | -956.30M | -886.40M | -1.74B | -41.20M | -256.50M | -234.89M | -3.20M | -36.72M |
| Sale of Investments | 1.16B | 1.14B | 435.70M | 211.90M | 169.70M | 58.06M | 25.09M | 16.91M |
| Investing Cash Flow | 203.50M | 242.80M | -1.31B | 164.30M | -93.10M | -179.67M | 20.87M | -20.11M |
| Financing Activities | ||||||||
| Long-Term Debt Issuance | — | — | — | — | — | 2.00M | — | — |
| Long-Term Debt Payments | — | — | — | — | -200,000 | -173,889 | -161,363 | -149,739 |
| Other Financing Charges | -17.00M | — | -4.60M | -29.30M | -600,000 | -3.42M | — | — |
| Financing Cash Flow | 370.20M | — | 260.00M | 467.07M | 136.30M | 164.56M | -161,363 | -149,739 |
| Other Cash Details | ||||||||
| End Cash Position | 317.20M | 86.80M | 112.80M | 588.40M | 9.20M | 3.19M | 30.91M | 5.09M |
| Income Tax Paid | 11.10M | 11.10M | — | — | — | — | — | — |
| Interest Paid | — | — | 100,000 | 100,000 | 100,000 | 39,476 | 32,393 | 46,552 |
| Free Cash Flow | -350.70M | -280.30M | 554.70M | -96.10M | -46.90M | -18.95M | 4.10M | -19.71M |
Error: Invalid format in Holders JSON file.
Article
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET.
Feb 3, 2025
Article
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Feb 1, 2025
Article
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention toward two innovative drugmakers. A couple of stocks in the volatile biopharmaceutical industry are poised to soar by the end of March.
Jan 21, 2025
